glycyl-glycyl-histamine | 172756-15-9

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: glycyl-glycyl-histamine
• 英文别名: GlyGlyHa；2-amino-N-[2-[2-(1H-imidazol-5-yl)ethylamino]-2-oxoethyl]acetamide
• CAS: 172756-15-9
• 化学式: C₉H₁₅N₅O₂
• 分子量: 225.25
• InChiKey: CPCGZZXIOHDNJR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.9
• 重原子数：
  16
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.44
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  glycyl-glycyl-histamine 在 copper(II) 作用下， 以 水 为溶剂， 生成
  参考文献：
  名称：

  Proton and Metal Ion Interactions with Glycylglycylhistamine, a Serum Albumin Mimicking Pseudopeptide

  摘要：

  The macro- and microprotonations of glycylglycylhistamine (GGHA) have been determined by combined potentiometric and H-1-NMR methods. The complexation of GGHA with Co(II), Ni(II), and Cu(II) has been studied by potentiometric, EPR, and H-1-NMR methods. In the pH range 3-11.2, more or less deprotonated monomeric complexes (MLH, ML, MLH(-1), MLH(-2), MLH(-3)) formed in all systems. In the case of Ni(II) and Cu(II) at physiological pH, the MLH(-2) species is predominant with four nitrogen coordination sites (one amino, two peptide, and one imidazole-N-3 nitrogens) in square planar arrangement. In Co(II) containing systems however, CoL is the predominant complex near pH 7 with a macrochelate coordination of terminal amino and imidazole nitrogens, while CoLH(-2) species forms at much higher pH. In accordance with NMR measurements, the formation of MLH(-3) species can be assigned to the further deprotonation of the N-1-pyrrolic nitrogen in the imidazole ring without metal coordination. The formation constants determined were compared with those of the analogous histidine derivatives. Single-crystal X-ray analysis of CuLH(-2). 3H(2)O verified the expected four nitrogen coordination in the equatorial plane of Cu(II).

  DOI：

  10.1021/ic950373e
• 作为产物：
  描述：

  组胺 在 盐酸 、 1-羟基苯并三唑 、 一水合肼 、 三乙胺 、 三氟乙酸 、 N,N'-二异丙基碳二亚胺 作用下， 以 1,4-二氧六环 、 乙醇 、 二氯甲烷 、 甲苯 、 乙腈 为溶剂， 反应 11.17h， 生成 glycyl-glycyl-histamine
  参考文献：
  名称：

  碳酸酐酶激活剂：氨基酰基/二肽基组胺衍生物与同工酶I，II和IV具有高亲和力，可作为有效的激活剂。

  摘要：

  组胺（Hst）与四溴邻苯二甲酸酐反应，并用三苯甲基磺酰氯保护其咪唑部分，然后进行肼解反应，得到N-1-三苯甲基磺酰-组胺，这是一种关键中间体，在其氨基乙基部分被进一步衍生。在咪唑类和氨基部分脱保护后，在碳二亚胺存在下，关键中间体与N-Boc-氨基酸/二肽（Boc-AA）反应，得到了一系列通式为AA-Hst的化合物（AA =氨基酰基；二肽基）。分析了新衍生物作为三种碳酸酐酶（CA）同工酶的激活剂，它们分别是hCA I，hCA II（胞质形式）和bCA IV（膜结合形式）。观察到针对所有三种同工酶的有效活化，尤其是针对hCA I和bCA IV的活化，其最佳化合物的亲和力在纳摩尔范围内。另一方面，hCA II可以被约10-20 nM的亲和力激活。这类新型的CA激活剂可能导致针对CA缺乏综合症（一种骨骼，脑和肾脏的遗传性疾病）的药物/诊断剂的开发。

  DOI：

  10.1016/s0968-0896(99)00227-8

文献信息

• AMIDE COMPOUNDS, METHODS FOR PREPARATION, AND USE THEREOF AS AGENTS FOR THE TREATMENT AND PREVENTION OF DISEASES CAUSED BY RNA- AND/OR DNA-CONTAINING VIRUSES, AND CONCOMITANT DISEASES
  申请人：OBSCHESTVO S OGRANICHENNOI OTVETSTVENNOSTIYU "PHARMENTERPRISES"

  公开号：US20170183318A1

  公开（公告）日：2017-06-29

  The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.

  本发明涉及医学，包括一种用于预防和治疗由RNA-和DNA-含病毒引起的疾病以及相关疾病的方法，其中该方法包括使用通式I的化合物或其药用可接受盐的有效量。该发明还涉及制备上述化合物的方法，用于预防或治疗由RNA-和DNA-含病毒引起的疾病的药物组合物，该组合物包括通式I的化合物或其药用可接受盐的有效量。该发明解决了提供一种新型药剂的目标，用于治疗属于肠病毒、副呼吸道病毒、呼吸道病毒、呼吸道病毒或阿尔法冠状病毒属的RNA-含病毒引起的疾病，和/或属于腺病毒科和/或疱疹病毒科的DNA-含病毒引起的疾病，并在预防和治疗哮喘急性发作、慢性阻塞性肺疾病、黏液囊病、结膜炎、胃肠炎、肝炎、心肌炎；在预防和治疗流涕、急性和感染性鼻炎、咽炎、鼻咽炎、扁桃体炎、喉炎、喉气管炎、喉气管支气管炎、支气管炎、支气管炎、肺炎或气道梗阻综合征方面具有有效性。
• Decomposition Kinetics of Ni(III)−Peptide Complexes with Histidine and Histamine as the Third Residue
  作者：Teweldemedhin M. Tesfai、Brandon J. Green、Dale W. Margerum

  DOI：10.1021/ic049338a

  日期：2004.10.1

  The transition from first- to second-order kinetics is attributed to the formation of an oxo-bridged Ni(III)-peptide dimer. The rates of decay of the Ni(III) complexes are general-base assisted with Bronsted beta values of 0.62 and 0.59 for Ni(III)Gly(2)HisGly and Ni(III)Gly(2)Ha, respectively. The coordination of Gly(2)HisGly and Gly(2)Ha to Ni(II) are examined by UV-vis and CD spectroscopy. The square

  Gly（2）HisGly和Gly（2）Ha的Ni（III）配合物的分解动力学研究是从p [H（+）] 3.5到10，其中His是l-组氨酸，Ha是组胺。在这些氧化还原反应中，至少两个Ni（III）络合物在氧化单个肽配体的同时被还原为Ni（II）。Ni（III）的流失速率在低pH值下为一阶，在pH 7.0到8.5之间为混合阶，而在较高pH下为二阶。从一阶动力学到二阶动力学的转变归因于氧代桥连的Ni（III）肽二聚体的形成。Ni（III）配合物的衰变速率是一般碱辅助的，对于Ni（III）Gly（2）HisGly和Ni（III）Gly（2）Ha的布朗斯泰德β值分别为0.62和0.59。Gly（2）HisGly和Gly（2）Ha与Ni（II）的配位通过UV-vis和CD光谱法检查。方形平面Ni（II）（H（-2）Gly（2）HisGly）（-）和Ni（II）（H（-2）Gly（2）Ha）络合物在高
• AMIDE COMPOUNDS AND METHODS FOR THE PRODUCTION AND USE THEREOF
  申请人：Obschestvo S Ogranichennoi Otvetstennostiyu "Pharmenterprises"

  公开号：EP3118211A1

  公开（公告）日：2017-01-18

  The present invention relates to medicine and includes a method for preventing and treating diseases caused by RNA- and DNA-containing viruses, and concomitant diseases, wherein the method comprises the use of an effective amount of compounds of general formula I or pharmaceutically acceptable salts thereof. The invention also relates to methods for preparing said compounds, pharmaceutical compositions for the prevention or treatment of diseases caused by RNA- and DNA-containing viruses, said compositions comprising an effective amount of a compound of formula I or a pharmaceutically acceptable salt thereof. The invention addresses the object of providing a novel agent effective in the treatment of diseases caused by an RNA-containing virus belonging to the Enterovirus, Metapneumovirus, Pneumovirus, Respirovirus, or Alfa-coronavirus genus, and/or by a DNA-containing virus belonging to the Adenoviridae and/or Herpesviridae family, and in the prevention and treatment of asthma exacerbation, chronic obstructive pulmonary disease, mucoviscidosis, conjunctivitis, gastroenteritis, hepatitis, myocarditis; in the prevention and treatment of rhinorrhea, acute and infectious rhinitis, pharyngitis, nasopharyngitis, tonsillitis, laryngitis, laryngotracheitis, laryngotracheobronchitis, bronchitis, bronchiolitis, pneumonia, or airway obstructive syndrome.

  本发明涉及医药，包括一种预防和治疗由含RNA和DNA病毒引起的疾病以及伴随疾病的方法，其中该方法包括使用有效量的通式I化合物或其药学上可接受的盐。本发明还涉及制备所述化合物的方法、用于预防或治疗由含 RNA 和 DNA 病毒引起的疾病的药物组合物，所述组合物包含有效量的通式 I 化合物或其药学上可接受的盐。本发明的目的是提供一种新型制剂，有效治疗由肠病毒属、偏肺病毒属、肺炎病毒属、呼吸道病毒属或阿法-冠状病毒属的含 RNA 病毒引起的疾病、和/或属于腺病毒科和/或疱疹病毒科的含 DNA 病毒，以及预防和治疗哮喘加重、慢性阻塞性肺病、粘液粘稠病、结膜炎、肠胃炎、肝炎、心肌炎；预防和治疗鼻炎、急性和感染性鼻炎、咽炎、鼻咽炎、扁桃体炎、喉炎、喉气管炎、喉气管支气管炎、支气管炎、支气管炎、肺炎或气道阻塞综合征。
• Large variations in acidity of terminal amide bonds in histamine-containing peptides as measured by proton DNMR
  作者：Jean-Jacques Delpuech、Delphine Champmartin、Katalin Selmeczi、Bernard Henry

  DOI：10.1016/j.tet.2014.07.024

  日期：2014.9

  The main objective of these studies is to quantitatively estimate pK variations of individual amide bonds as a function of the ionization state of end groups in peptides, determined on measuring macro- and micro- (if any) ionization constants. H-1 NMR spectra of aqueous solutions of eight model substrates were consequently recorded using a water suppression sequence, within large pH ranges. A set of programs was devised to treat NMR data over the entirety of pH-dependent NMR patterns, in order to smooth out errors arising in handling individual spectra. Rates of amide proton abstraction by hydroxide ions were obtained from the coalescence of methylene coupled protons and the decrease of NH bond signal intensities, allowing us to estimate and discuss peptide pKs on assuming back reprotonation at a diffusion-limited rate. Cis-trans isomerization rates in two substrates bearing a tert-Butyloxycarbonyl terminal group were put in parallel with the acidity of carbamic protons. (C) 2014 Elsevier Ltd. All rights reserved.